An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The treatment, tulisokibart, ...

Add Yahoo as a preferred source to see more of our stories on Google. “Debilitating digestive issues dominated my life because I couldn’t go longer than a half hour without going to the bathroom,” ...

Ulcerative Colitis Market grows at 5.4% CAGR (2025–2033), reaching US$ 12.79 Billion on rising biologic adoption, biosimilars, and personalized IBD therapies. North America leads the ulcerative ...

The FDA approved Omvoh, a medication that treats ulcerative colitis developed by drugmaker Eli Lilly. The injection is the first treatment for ulcerative colitis that targets p19, a specific protein ...

The American Gastroenterological Association has updated guidance for the treatment of ulcerative colitis to recommend using higher efficacy drugs in earlier stages of treatment, Medscape Medical News ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. This is an exciting time to think about ...

Mirikizumab treatment is safe and efficacious for ulcerative colitis up to 152 weeks in those with and without previous biologic therapy failure. Mirikizumab treatment for 152 weeks is associated with ...

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...

Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD). It causes painful sores and inflammation deep inside your colon and rectum. That can lead to hard-to-manage symptoms like ...

While complementary therapies won’t treat the underlying cause of ulcerative colitis (UC), they can help you manage your symptoms and improve your overall quality of life. Ulcerative colitis (UC) is ...